166 related articles for article (PubMed ID: 24590575)
1. Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan.
Kurita T; Kitaichi T; Nagao T; Miura T; Kitazono Y
Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):372-81. PubMed ID: 24590575
[TBL] [Abstract][Full Text] [Related]
2. Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan.
Kurita T; Kitaichi T; Nagao T; Miura T; Kitazono Y
Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):361-71. PubMed ID: 24585486
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
Castillo SA; Hernandez JE; Brothers CH
Drug Saf; 2006; 29(9):811-26. PubMed ID: 16944966
[TBL] [Abstract][Full Text] [Related]
4. Safety and Effectiveness Analyses of Dolutegravir/Lamivudine in Patients with HIV: 2-Year Report of Post-Marketing Surveillance in Japan.
Tofukuji A; Hongo H; Nagao T; Sebata A; Suzuki M; Maeno Y; Kurosaki E; Fukuda A; Watanabe T
Adv Ther; 2023 Apr; 40(4):1884-1898. PubMed ID: 36840899
[TBL] [Abstract][Full Text] [Related]
5. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).
Sosa N; Hill-Zabala C; Dejesus E; Herrera G; Florance A; Watson M; Vavro C; Shaefer M
J Acquir Immune Defic Syndr; 2005 Dec; 40(4):422-7. PubMed ID: 16280696
[TBL] [Abstract][Full Text] [Related]
6. Safety analysis of Lexiva tablets 700 (fosamprenavir calcium hydrate) in post-marketing surveillance in Japan.
Fukuda A; Nagao T; Kitaichi T; Koga I; Kobayashi A; Miura T
Curr Med Res Opin; 2020 Mar; 36(3):455-464. PubMed ID: 31794279
[No Abstract] [Full Text] [Related]
7. Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012.
Galindo J; Amariles P; Mueses-Marín HF; Hincapié JA; González-Avendaño S; Galindo-Orrego X
BMC Infect Dis; 2016 Oct; 16(1):532. PubMed ID: 27716093
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
[No Abstract] [Full Text] [Related]
9. Abacavir and lamivudine combination.
Somboonwit C; Kurtyka D; Velez AP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1599-606. PubMed ID: 19929448
[TBL] [Abstract][Full Text] [Related]
10. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
[TBL] [Abstract][Full Text] [Related]
12. Lamivudine/zidovudine/abacavir: triple combination tablet.
Ibbotson T; Perry CM
Drugs; 2003; 63(11):1089-98; discussion 1099-1100. PubMed ID: 12749741
[TBL] [Abstract][Full Text] [Related]
13. Two-once-daily fixed-dose NRTI combinations for HIV.
Med Lett Drugs Ther; 2005 Feb; 47(1203):19-20. PubMed ID: 15767973
[TBL] [Abstract][Full Text] [Related]
14. Incidence of abacavir hypersensitivity reactions in euroSIDA.
Bannister WP; Friis-Møller N; Mocroft A; Viard JP; van Lunzen J; Kirk O; Gargalianos P; Bánhegyi D; Chiesi A; Lundgren JD;
Antivir Ther; 2008; 13(5):687-96. PubMed ID: 18771052
[TBL] [Abstract][Full Text] [Related]
15. Abacavir sulfate, lamivudine, and zidovudine (Trizivir).
Porche D
J Assoc Nurses AIDS Care; 2001; 12(6):88-90. PubMed ID: 11723917
[TBL] [Abstract][Full Text] [Related]
16. Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan.
Hongo H; Nagao T; Nakamura K; Kitaichi T; Maeno Y; Tokunaga T; Fukuda A; Koga I
Adv Ther; 2021 Aug; 38(8):4480-4504. PubMed ID: 34275116
[TBL] [Abstract][Full Text] [Related]
17. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
18. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.
Hetherington S; McGuirk S; Powell G; Cutrell A; Naderer O; Spreen B; Lafon S; Pearce G; Steel H
Clin Ther; 2001 Oct; 23(10):1603-14. PubMed ID: 11726000
[TBL] [Abstract][Full Text] [Related]
19. Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
Podzamczer D; Imaz A; Perez I; Viciana P; Valencia E; Curto J; Martín T; Castaño M; Rojas J; Espinosa N; Moreno V; Asensi V; Iribarren JA; Clotet B; Force L; Bachiller P; Knobel H; López Bernaldo De Quirós JC; Blanco JR; Rozas N; Vergas J; Ocampo A; Camacho A; Flores J; Gomez-Sirvent JL;
J Antimicrob Chemother; 2014 Sep; 69(9):2536-40. PubMed ID: 24833755
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.
Curran A; Rojas J; Cabello A; Troya J; Imaz A; Domingo P; Martinez E; Ryan P; Górgolas M; Podzamczer D; Knobel H; Gutiérrez F; Ribera E
J Antimicrob Chemother; 2016 Dec; 71(12):3510-3514. PubMed ID: 27591292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
